RECRUITINGOBSERVATIONAL
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
About This Trial
To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan
Who May Be Eligible (Plain English)
Who May Qualify:
1\. Patients who are treated with DAA and have willingness to participate in this registry.
Who Should NOT Join This Trial:
Chronic hepatitis C patients who are unwilling to participate in the study and do not provide written willing to sign a consent form for participation.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1\. Patients who are treated with DAA and have willingness to participate in this registry.
Exclusion Criteria:
Chronic hepatitis C patients who are unwilling to participate in the study and do not provide written informed consent for participation.
Treatments Being Tested
OTHER
directly acting antivirals (DAAs)
Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
Locations (1)
HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Kaohsiung City, Taiwan